Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 11—November 2016
Letter

Marseillevirus in the Pharynx of a Patient with Neurologic Disorders

On This Page
Figures
Article Metrics
14
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: Marseilleviridae is a recently described family of giant amebal viruses (1). Although Marseillevirus, its founding member, and subsequently discovered representatives were isolated primarily from environmental water, marseilleviruses have been recovered from humans (2,3). Senegalvirus, a close Marseillevirus relative, was serendipitously isolated from a healthy man’s feces (2). Metagenomics then unexpectedly identified Marseillevirus-related sequences in blood of healthy donors (3), which was confirmed by PCR, fluorescence in situ hybridization, and serologic testing. Further PCR and serologic studies suggested substantial exposure of humans to marseilleviruses (4,5).

During assessment of Marseillevirus serology at Institut Hospitalo-Universitaire (IHU) Méditerranée Infection (Marseille, France), we found serum from an 11-month-old boy with lymphadenitis that exhibited a high Marseillevirus IgG titer; the virus was detected by PCR in serum and by fluorescence in situ hybridization and immunohistochemistry in the lymph node (6). Subsequently, the hospital implemented systematic Marseillevirus PCR in cases of gastroenteritis or pharyngitis, which led to detection of Marseillevirus DNA in pharyngeal and blood samples from a 20-year-old man. He had sought treatment in November 2013 for a 2-day febrile gastroenteritis that was treated with amoxicillin and acetaminophen; however, several hours later, his fever reached 40°C, and intense headache and stiff neck led to his hospitalization. No adenopathy was palpable. Laboratory analyses showed elevated C-reactive protein (194 mg/L), elevated bilirubin (44 µmol/L), low platelet count (120 G/L), and elevated polynuclear cell count (9 G/L). Cerebrospinal fluid (CSF) was clear and acellular; the CSF to blood glucose ratio was normal, but the protein level was elevated (0.73 g/L).

We tested CSF and feces by culture, PCR, or immunoenzyme assay for common infectious agents of meningitis, encephalitis, and gastroenteritis, including enteroviruses, herpesviruses, Neisseria meningitidis, Streptococcus pneumoniae, caliciviruses, rotavirus, adenoviruses, and Clostridium difficile. All results were negative. Feces were also negative for Marseillevirus DNA. Serologic test results were negative for HIV and cytomegalovirus. However, a pharyngeal sample was positive for Marseillevirus in routine diagnosis using the PCR system ORF152 (3); sequencing showed 100% nucleotide identity with the Marseillevirus genome (http://www.mediterranee-infection.com/article.php?laref=495&titre=marseillevirus-pharynx). Retrospective testing of CSF for Marseillevirus DNA yielded negative results.

The patient recovered after receiving ciprofloxacin and was discharged after 72 hours. One year later, he exhibited vertigo and a 7-kg weight loss over 4 months, although no additional episode of gastroenteritis or fever had occurred. He reported a slight impairment of cognitive functions (i.e., memory, attention), but clinical examination and cerebral positron emission and computed tomographic scan results were normal. Vertigo was attributed to vestibular deficiency and treated with betahistine. CSF testing still showed an isolated high protein level (0.68 G/L) without hypercellularity but negative results for bacteria and viruses. However, Marseillevirus DNA was detected by 2 PCR systems that target a helicase gene: blood testing using the ORF152 PCR and pharyngeal swab specimen testing using the HelF6R6 PCR system (primers: 5′-GAGGATGTACGGAAGGTC-3′ [forward]; 5′-GTCCTTCACCTGTTCTTCC-3′ [reverse]). Sequence identities were 99% and 100%, respectively, with Marseillevirus (GenBank accession no. KU933837; http://www.mediterranee-infection.com/article.php?laref=495&titre=marseillevirus-pharynx). In addition, Marseillevirus IgG was detected by indirect immunofluorescence assay; serum samples that were negative or positive for Marseillevirus IgG in previous experiments were used as negative and positive controls, respectively (4). After 2 months, the patient’s general condition had improved, and neurocognitive and vestibular symptoms resolved.

Figure

Thumbnail of Marseillevirus sequences and serologic analysis for a 20-year-old man in Marseille, France, who initially sought treatment in November 2013 for a 2-day febrile gastroenteritis. A) Alignment of the sequence obtained in November 2014 from the blood of the case-patient with sequences from Marseillevirus and other related viruseses. GenBank accession nos.: Marseillevirus, GU071086.1; Melbournevirus, KM275475.1; Fontaine Saint-Charles virus, KF582416.1; Senegalvirus, KF582412.1; Marseill

Figure. Marseillevirus sequences and serologic analysis for a 20-year-old man in Marseille, France, who initially sought treatment in November 2013 for a 2-day febrile gastroenteritis. A) Alignment of the sequence obtained in...

Marseillevirus presence in the case-patient is indisputable, as supported by specific molecular detection and sequencing of 2 sequential pharyngeal swab specimens and of blood, with concurrent IgG positivity (Figure). The presence of the virus in 2 samples collected at a 1-year interval suggests chronic carriage.

Several reports showed that giant viruses may be common in humans, but association with pathogenicity was documented differently, depending on the viruses. Thus, many serologic, virologic, and clinical findings argued for a causative role of mimiviruses in pneumonia, which was strengthened in 2013 by the culture isolation of mimiviruses from 2 pneumonia patients (7,8). In addition, Acanthocystis turfacea chlorella virus-1, a phycodnavirus that infects algae, was detected by metagenomics in human oropharyngeal samples, and this association was further confirmed by PCR in 92 samples, with a prevalence of 44% (9). Unexpectedly, DNA detection of this virus was associated with a decrease in cognitive performance in these patients; such cognitive disorders were also observed in mice inoculated with this virus.

The presence of Marseillevirus in healthy humans was described by high-throughput sequencing and subsequent culture isolation from feces (2), then by metagenomics in blood donors’ blood (3). Unexpectedly, seroprevalence studies conducted in the general population showed high (up to 13%) positivity rates of Marseillevirus IgG, which suggested a common human exposure (35). Presence of Marseillevirus in a symptomatic human was reported in 2013 in an 11-month-old boy with lymphadenitis and possibly corresponded to a primary infection (6). Marseillevirus was then detected in the lymph node of a 30-year-old woman with Hodgkin’s lymphoma (10). In the case we describe, Marseillevirus was detected in the human oropharynx in association with cognitive impairment and possible chronic carriage with concurrent persistence of clinical signs. The involvement of Marseillevirus in these symptoms cannot be established here, but these findings warrant further investigation.

Top

Sarah Aherfi, Philippe Colson, and Didier RaoultComments to Author 
Author affiliations: Aix-Marseille University, Marseille, France; Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille

Top

References

  1. Boyer  M, Yutin  N, Pagnier  I, Barrassi  L, Fournous  G, Espinosa  L, et al. Giant Marseillevirus highlights the role of amoebae as a melting pot in emergence of chimeric microorganisms. Proc Natl Acad Sci U S A. 2009;106:2184853.DOIPubMedGoogle Scholar
  2. Lagier  JC, Armougom  F, Million  M, Hugon  P, Pagnier  I, Robert  C, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect. 2012;18:118593.DOIPubMedGoogle Scholar
  3. Popgeorgiev  N, Boyer  M, Fancello  L, Monteil  S, Robert  C, Rivet  R, et al. Marseillevirus-like virus recovered from blood donated by asymptomatic humans. J Infect Dis. 2013;208:104250.DOIPubMedGoogle Scholar
  4. Popgeorgiev  N, Colson  P, Thuret  I, Chiarioni  J, Gallian  P, Raoult  D, et al. Marseillevirus prevalence in multitransfused patients suggests blood transmission. J Clin Virol. 2013;58:7225.DOIPubMedGoogle Scholar
  5. Mueller  L, Baud  D, Bertelli  C, Greub  G. Lausannevirus seroprevalence among asymptomatic young adults. Intervirology. 2013;56:4303.DOIPubMedGoogle Scholar
  6. Popgeorgiev  N, Michel  G, Lepidi  H, Raoult  D, Desnues  C. Marseillevirus adenitis in an 11-month-old child. J Clin Microbiol. 2013;51:41025.DOIPubMedGoogle Scholar
  7. Saadi  H, Pagnier  I, Colson  P, Cherif  JK, Beji  M, Boughalmi  M, et al. First isolation of Mimivirus in a patient with pneumonia. Clin Infect Dis. 2013;57:e12734.DOIPubMedGoogle Scholar
  8. Saadi  H, Reteno  DG, Colson  P, Aherfi  S, Minodier  P, Pagnier  I, et al. Shan virus: a new mimivirus isolated from the stool of a Tunisian patient with pneumonia. Intervirology. 2013;56:4249.DOIPubMedGoogle Scholar
  9. Yolken  RH, Jones-Brando  L, Dunigan  DD, Kannan  G, Dickerson  F, Severance  E, et al. Chlorovirus ATCV-1 is part of the human oropharyngeal virome and is associated with changes in cognitive functions in humans and mice. Proc Natl Acad Sci U S A. 2014;111:1610611.DOIPubMedGoogle Scholar
  10. Aherfi  S, Colson  P, Audoly  G, Nappez  C, Xerri  L, Valensi  A, et al. Marseillevirus in lymphoma: a giant in the lymph node. Lancet Infect Dis. 2016;Aug 5:S1473-3099(16)30051-2. DOIPubMedGoogle Scholar

Top

Figure

Top

Cite This Article

DOI: 10.3201/eid2211.160189

Related Links

Top

Table of Contents – Volume 22, Number 11—November 2016

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Didier Raoult, Unité des Rickettsies, Faculté de Médecine, URMITE UM 63 CNRS 7278 IRD 198 INSERM U1095, Aix-Marseille University, 13385 Marseille CEDEX 05, France

Send To

10000 character(s) remaining.

Top

Page created: October 19, 2016
Page updated: October 19, 2016
Page reviewed: October 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external